Literature DB >> 7922793

Comparison of the acute biological action of injectable salmon calcitonin and an injectable and oral calcitonin analogue.

J P Devogelaer1, M Azria, M Attinger, G Abbiati, C Castiglioni, C Nagant de Deuxchaisnes.   

Abstract

In most countries, calcitonin is available in the form of injections, and less frequently as an intranasal spray. An oral route of administration should improve compliance. In a preliminary feasibility study, we have compared the acute biological action of injectable salmon calcitonin (50 IU), with the injectable calcitonin analogue ASC 710 (0.2 mg) and oral ASC 710 (20 mg) in 6 patients suffering from active Paget's disease of bone. The intensity and duration of the biological response were not significantly different in the 3 modes of therapy. In conclusion, the oral calcitonin analogue ASC 710 possesses an antiresorbing activity in Paget's disease comparable to that of an injection of salmon calcitonin which demonstrates that it can cross the intestinal barrier.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7922793     DOI: 10.1007/bf00310172

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  7 in total

1.  A method for the rapid determination of alkaline phosphates with five cubic millimeters of serum.

Authors:  O A BESSEY; O H LOWRY; M J BROCK
Journal:  J Biol Chem       Date:  1946-07       Impact factor: 5.157

2.  Nasal calcitonin for treatment of established osteoporosis.

Authors:  K Overgaard; B J Riis; C Christiansen; J Pødenphant; J S Johansen
Journal:  Clin Endocrinol (Oxf)       Date:  1989-04       Impact factor: 3.478

3.  Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment.

Authors:  R Civitelli; S Gonnelli; F Zacchei; S Bigazzi; A Vattimo; L V Avioli; C Gennari
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

4.  Monitoring of free and total urinary pyridinoline and deoxypyridinoline in healthy volunteers: sample relationships between 24-h and fasting early morning urine concentrations.

Authors:  G Abbiati; F Bartucci; A Longoni; G Fincato; S Galimberti; M Rigoldi; C Castiglioni
Journal:  Bone Miner       Date:  1993-04

5.  New modes of administration of salmon calcitonin in Paget's disease. Nasal spray and suppository.

Authors:  C Nagant de Deuxchaisnes; J P Devogelaer; J P Huaux; J P Dufour; W Esselinckx; J P Engelbeen; P Stasse; P Hermans; J P de Buisseret
Journal:  Clin Orthop Relat Res       Date:  1987-04       Impact factor: 4.176

6.  Effectiveness of salmon calcitonin administered as suppositories in tumor-induced hypercalcemia.

Authors:  D Thiébaud; P Burckhardt; P Jaeger; M Azria
Journal:  Am J Med       Date:  1987-04       Impact factor: 4.965

7.  Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone.

Authors:  H I Harinck; O L Bijvoet; H J Blanksma; P J Dahlinghaus-Nienhuys
Journal:  Clin Orthop Relat Res       Date:  1987-04       Impact factor: 4.176

  7 in total
  2 in total

Review 1.  Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis.

Authors:  J A Knopp-Sihota; C V Newburn-Cook; J Homik; G G Cummings; D Voaklander
Journal:  Osteoporos Int       Date:  2011-06-10       Impact factor: 4.507

Review 2.  Corticosteroid-induced bone loss. Prevention and management.

Authors:  C Picado; M Luengo
Journal:  Drug Saf       Date:  1996-11       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.